Amphotericin B Respiratory Formulations for Low-Toxicity Absorption

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for respiratory tract inflammation and infection, such as asthma, fail to address the underlying infective causes and often cause adverse reactions, and existing formulations of Amphotericin B for oral administration have low absorption and high toxicity.

Innovation Solution

A combination therapy of Amphotericin B with one or more antibiotics, formulated as nanosuspensions, encochleated formulations, or lipid-based preparations, administered orally or by inhalation, to target fungal and bacterial infections in the respiratory tract.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional antifungal agents (terbinafine, itraconazole) are used to treat respiratory fungal infections, then antifungal efficacy is achieved, but cross-reactions with other drugs and liver damage occur

Engineering Contradiction:

Improveantifungal efficacyVSAvoidcross-reactions and liver damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical structure parameters of conventional antifungal agents by introducing fluorine atoms at specific positions (e.g., 2-fluoroterbinafine, 4-fluoroterbinafine) to modify pharmacological properties, reduce cross-reactions, and eliminate hepatotoxicity while maintaining antifungal activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates analogs and derivatives of existing antifungal agents (terbinafine, itraconazole) by copying their core structures and modifying them with fluorine substitutions, thereby replicating the therapeutic effect while eliminating harmful side effects

Inventive Principle:

Principle #26Copying

2Quantity of substance

If Amphotericin B is formulated for oral administration using conventional methods (nanosuspensions, lipid-based formulations), then some absorption is achieved, but absorption remains low and toxicity is high

Engineering Contradiction:

Improveabsorption of Amphotericin BVSAvoidtoxicity

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent uses encochleated formulations composed of phospholipids and cholesterol forming a composite material structure that encapsulates Amphotericin B, improving its solubility and absorption while reducing toxicity through the protective lipid matrix

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies the physical and chemical parameters of Amphotericin B by incorporating it into encochleated structures with specific phospholipid compositions and cholesterol ratios, thereby enhancing bioavailability and reducing harmful effects

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If steroids and immunomodulators are used to treat respiratory inflammation, then inflammatory symptoms are reduced, but underlying infective causes are not addressed

Engineering Contradiction:

Improveinflammatory symptomsVSAvoidtreatment of underlying cause

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

Instead of treating only the inflammatory symptoms with steroids, the patent inverts the approach by directly targeting the underlying fungal and bacterial infections with fluorinated antifungals and antibiotics, thereby addressing the root cause rather than just the symptoms

Inventive Principle:

Principle #13The other way round (Inversion)

4Object-affected harmful factors

If emollients are used by patients to minimize fungal spore inhalation, then spore protection is improved, but patient compliance is reduced due to treatment restrictions

Engineering Contradiction:

Improvefungal spore inhalationVSAvoidpatient compliance

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent converts the harmful fungal spores into a treatable condition by using fluorinated antifungal agents that specifically target and eliminate the spores, thereby transforming the need for restrictive emollient use into an effective pharmacological treatment that allows patients to discontinue emollients

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260027140A1Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa

Publication Date: 2026.01.29 ATOPIC MEDICAL INC

AI summary

Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.